• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

危重症患者的环丙沙星药代动力学:一项前瞻性队列研究。

Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.

作者信息

van Zanten Arthur R H, Polderman Kees H, van Geijlswijk Ingeborg M, van der Meer Gert Y G, Schouten Marinus A, Girbes Armand R J

机构信息

Department of Intensive Care, Gelderse Vallei Hospital, 6710 HN Ede, The Netherlands.

出版信息

J Crit Care. 2008 Sep;23(3):422-30. doi: 10.1016/j.jcrc.2007.11.011. Epub 2008 Apr 18.

DOI:10.1016/j.jcrc.2007.11.011
PMID:18725050
Abstract

PURPOSE

Optimal dosing of antibiotics is important for efficacy and avoidance of resistance. Fluoroquinolones are frequently used to treat severe infections in critically ill patients. We studied ciprofloxacin pharmacokinetics after administration of 400 mg twice a day (bid) intravenously (IV).

MATERIAL AND METHODS

Serum concentrations were measured in 32 intensive care unit patients (age, 68.7 +/- 17.4 years; Sepsis-related Organ Failure Assessment (SOFA) scores, 7.3 +/- 3.4). Blood samples were drawn at 7 time points after ciprofloxacin infusion. We evaluated whether areas under the curve (AUCs) exceeded minimal inhibitory concentration (MIC) values of 0.125, 0.25, 0.5, 1.0, and 2.0 mg/L by 125 times and peak concentrations (C(max)) 10 x MIC (C(max)/MIC >10).

RESULTS

The AUC/MIC more than 125 was achieved in 100% for MIC 0.125. For MIC values 0.25, 0.5, 1.0, and 2.0, results were 84%, 31%, 3%, and 0%, respectively (P < .01). The C(max)/MIC more than 10 for MIC values of 0.125, 0.25, 0.5, 1.0, and 2.0 was realized in 100%, 97%, 69%, 25%, and 0%, respectively (P < .01). Female sex, SOFA(pulmonary) points, and SOFA(renal) points predicted higher AUC. Cumulative SOFA scores were most predictive of high AUCs.

CONCLUSIONS

Ciprofloxacin 400 mg bid IV leads to inadequate AUC/MIC and C(max)/MIC ratios in many cases. Effective killing concentrations were only achieved in pathogens with MIC less than 0.25. As bacteria in intensive care unit patients often exceed this threshold, we recommend to use higher doses of ciprofloxacin (1200 mg daily) to ensure optimal bacterial killing and avoid antibiotic resistance.

摘要

目的

抗生素的最佳剂量对于疗效和避免耐药性至关重要。氟喹诺酮类药物常用于治疗重症患者的严重感染。我们研究了每天两次静脉注射(IV)400毫克环丙沙星后的药代动力学。

材料与方法

对32名重症监护病房患者(年龄68.7±17.4岁;脓毒症相关器官功能衰竭评估(SOFA)评分7.3±3.4)进行血清浓度测定。在环丙沙星输注后的7个时间点采集血样。我们评估曲线下面积(AUC)是否超过最低抑菌浓度(MIC)值(0.125、0.25、0.5、1.0和2.0毫克/升)的125倍以及峰值浓度(C(max))是否超过10×MIC(C(max)/MIC>10)。

结果

对于MIC值0.125,AUC/MIC超过125的比例达到100%。对于MIC值0.25、0.5、1.0和2.0,结果分别为84%、31%、3%和0%(P<.01)。对于MIC值0.125、0.25、0.5、1.0和2.0,C(max)/MIC超过10的比例分别为100%、97%、69%、25%和0%(P<.01)。女性、SOFA(肺部)评分和SOFA(肾脏)评分预示着更高的AUC。累积SOFA评分对高AUC的预测性最强。

结论

每天两次静脉注射环丙沙星400毫克在许多情况下会导致AUC/MIC和C(max)/MIC比值不足。仅在MIC小于0.25的病原体中能达到有效的杀菌浓度。由于重症监护病房患者体内的细菌常常超过这个阈值,我们建议使用更高剂量的环丙沙星(每日1200毫克)以确保最佳的细菌杀灭效果并避免抗生素耐药性。

相似文献

1
Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.危重症患者的环丙沙星药代动力学:一项前瞻性队列研究。
J Crit Care. 2008 Sep;23(3):422-30. doi: 10.1016/j.jcrc.2007.11.011. Epub 2008 Apr 18.
2
Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.群体药代动力学及应用蒙特卡洛模拟评估目前推荐的囊性纤维化成年患者环丙沙星给药方案
Antimicrob Agents Chemother. 2001 Dec;45(12):3468-73. doi: 10.1128/AAC.45.12.3468-3473.2001.
3
Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations.通过群体药代动力学-药效学分析和蒙特卡罗模拟优化重症监护病房患者的环丙沙星剂量。
J Antimicrob Chemother. 2011 Aug;66(8):1798-809. doi: 10.1093/jac/dkr220. Epub 2011 Jun 8.
4
Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.在突变选择窗内模拟的环丙沙星浓度下耐甲氧西林金黄色葡萄球菌的富集:推注与持续输注
Int J Antimicrob Agents. 2008 Dec;32(6):488-93. doi: 10.1016/j.ijantimicag.2008.06.031. Epub 2008 Sep 14.
5
Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.利奈唑胺在重症脓毒症患者中的药代动力学/药效学特征:间断输注与持续输注对比
Int J Antimicrob Agents. 2008 Feb;31(2):122-9. doi: 10.1016/j.ijantimicag.2007.09.009. Epub 2007 Dec 4.
6
Pharmacokinetics of enrofloxacin in turkeys.恩诺沙星在火鸡体内的药代动力学。
Res Vet Sci. 2007 Jun;82(3):392-7. doi: 10.1016/j.rvsc.2006.09.004. Epub 2006 Nov 14.
7
Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection.支持提高环丙沙星 AUC24/MIC 目标值以治疗肠杆菌科血流感染。
J Antimicrob Chemother. 2010 Aug;65(8):1725-32. doi: 10.1093/jac/dkq211. Epub 2010 Jun 17.
8
Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches.环丙沙星在重症患者中的应用:药代动力学和药效学方法
Int J Antimicrob Agents. 2008 Dec;32(6):505-10. doi: 10.1016/j.ijantimicag.2008.05.019. Epub 2008 Sep 2.
9
Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis.厄他培南每日一次给药在重症脓毒症危重症患者中的药代动力学
Int J Antimicrob Agents. 2009 May;33(5):432-6. doi: 10.1016/j.ijantimicag.2008.10.005. Epub 2008 Dec 16.
10
Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit.加替沙星在医学重症监护病房重症成年患者中的药代动力学和药效学评估。
Int J Antimicrob Agents. 2007 Jun;29(6):715-23. doi: 10.1016/j.ijantimicag.2007.02.006. Epub 2007 Apr 11.

引用本文的文献

1
Risk Factors Associated with Antibiotic Exposure Variability in Critically Ill Patients: A Systematic Review.危重症患者抗生素暴露变异性的相关危险因素:一项系统评价
Antibiotics (Basel). 2024 Aug 24;13(9):801. doi: 10.3390/antibiotics13090801.
2
Oral Antibiotics for Bacteremia and Infective Endocarditis: Current Evidence and Future Perspectives.用于治疗菌血症和感染性心内膜炎的口服抗生素:当前证据与未来展望
Microorganisms. 2023 Dec 18;11(12):3004. doi: 10.3390/microorganisms11123004.
3
Inoculum-Based Dosing: A Novel Concept for Combining Time with Concentration-Dependent Antibiotics to Optimize Clinical and Microbiological Outcomes in Severe Gram Negative Sepsis.
基于接种量的给药:一种将时间与浓度依赖性抗生素相结合以优化重症革兰氏阴性菌败血症临床和微生物学结果的新概念。
Antibiotics (Basel). 2023 Oct 31;12(11):1581. doi: 10.3390/antibiotics12111581.
4
24/7 Therapeutic Drug Monitoring of Beta-Lactam Antibiotics with CLAM-2000.使用CLAM - 2000对β-内酰胺类抗生素进行全天候治疗药物监测。
Antibiotics (Basel). 2023 Oct 10;12(10):1526. doi: 10.3390/antibiotics12101526.
5
The Significance of Bayesian Pharmacokinetics in Dosing for Critically Ill Patients: A Primer for Clinicians Using Vancomycin as an Example.贝叶斯药代动力学在危重症患者给药中的意义:以万古霉素为例的临床医生入门指南
Antibiotics (Basel). 2023 Sep 13;12(9):1441. doi: 10.3390/antibiotics12091441.
6
Efficient Removal of Ciprofloxacin from Contaminated Water via Polystyrene Anion Exchange Resin with Nanoconfined Zero-Valent Iron.通过含纳米限域零价铁的聚苯乙烯阴离子交换树脂从受污染水中高效去除环丙沙星
Nanomaterials (Basel). 2022 Dec 26;13(1):116. doi: 10.3390/nano13010116.
7
Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial.精准用药:即时、床边、数据驱动和个体化的脓毒症或感染性休克危重症患者抗生素治疗——一项两中心随机临床试验。
Crit Care. 2022 Sep 5;26(1):265. doi: 10.1186/s13054-022-04098-7.
8
Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study.口服和静脉给予环丙沙星在(病态)肥胖和非肥胖个体中的药代动力学:一项前瞻性临床研究。
Clin Pharmacokinet. 2022 Aug;61(8):1167-1175. doi: 10.1007/s40262-022-01130-5. Epub 2022 Jun 1.
9
No Time Dependence of Ciprofloxacin Pharmacokinetics in Critically Ill Adults: Comparison of Individual and Population Analyses.环丙沙星在危重症成年患者中的药代动力学无时间依赖性:个体分析与群体分析的比较
Pharmaceutics. 2021 Jul 27;13(8):1156. doi: 10.3390/pharmaceutics13081156.
10
Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens.儿童静脉和口服环丙沙星的群体药代动力学研究,以优化给药方案。
Eur J Clin Pharmacol. 2021 Nov;77(11):1687-1695. doi: 10.1007/s00228-021-03174-1. Epub 2021 Jun 23.